Double Randomized and Placebo Controlled Trail of Sanchitongshu Combined Antiplatelet Drug to Prevent Ischemic Stroke

Ischemic Stroke Clinical Trial

Official title:

The Randomized, Double-blind, Placebo-controlled Clinical Trail of Sanchitongshu Combined Antiplatelet Drug to Prevent High-risk Ischemic Stroke Recurrence

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04142151
• Other study ID #: XH-19-007
• Status: Recruiting
• Phase: N/A
• Start date: September 1, 2019
• Est. completion date: December 31, 2020

Study information

• Verified date: September 2019
• Source: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
• Contact: Zhiyin Lou, Doctor
• Phone: 86-021-25077504
• Email: louzhiyin2003[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical trail will evaluate the effect of Sanchitongshu combined with antiplatelet drugs (Aspirin or Clopidogrel) in the treatment of high-risk ischemic stroke patients in adults. Half of participants will receive SanchiTongshu and one of antiplatelet drugs (Aspirin or Clopidogrel) in combination, while the other half will receive a placebo and one of antiplatelet drugs (Aspirin or Clopidogrel).

Description:

The aim of this clinical trail is to evaluate the effect of Sanchitongshu in the treatment of high-risk ischemic stroke patients in adults. All patients included in the study should meet the inclusion criteria. All participants will receive one of antiplatelet drugs (Aspirin or Clopidogrel). Half of participants will receive Sanchitongshu and Aspirin or Clopidogrel, while the other half will receive a placebo and Aspirin or Clopidogrel. All participants will be assigned to either the active group or the control group randomly. During the clinical trail both doctors and patients are double-blind except serious adverse events occurred.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: December 31, 2020
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Age from 20yrs to 85yrs;

2. Anticipated patients within 8-90 days without cardiac ischemic stroke; Responsible lesions of all cases must be confirmed by a head MRI;

3. have ability to take the drugs;

4. No serious complications, liver and kidney function is normal;

5. At least one of the following (a-c):

1. Confirmed by MRA, CTA or DSA that stenosis of intracranial aorta beyond 50% (in A2, M2 or P2)

2. Confirmed by MRA, CTA or DSA that stenosis of cranial artery beyond 50% (carotid artery, intra-carotid artery, vertebral artery, head artery, or lower collarbone artery)

3. ESRS score beyond 3

6. Take Clopidogre or aspirin alone for antiplatelet treatment with informed consent

7. Willing to participate in the clinical trial and willing to be followed up with, have signed informed consent

Exclusion Criteria:

1. Younger than 20 yrs or elder than 85 yrs;

2. The neurological function defects caused by brain hemorrhage or other conditions (e.g. vascular malformations, tumors, abscesses or other non-ischemic cerebrovascular diseases);

3. Isolated sensory symptoms (e.g. numbness), isolated visual abnormalities, isolated dizziness and dizziness but have no responsibility lesions in head MRI;

4. Stroke is caused by angiography or surgery operation;

5. Stroke caused by cardio-induced embolism according to TOAST;

6. Anticoagulant evidence (heart thrombosis, such as atrial fibrillation, heart valve replacement surgery operation)

7. Contraindications of MRI examination, such as claustrophobia or implanted pacemakers

8. Severe heart and lung impairment; liver function laboratory indicator AST or ALT is 2x maximum normal value, or renal function laboratory indicator serum creatinine is 1.5X maximum normal value;

9. Plan to accept vascular surgery during the trial period (e.g. epidermal angioplasty, stent placement and bypass transplants, etc.); Surgical or interventional treatment requires discontinuation of research drugs

10. History of drug elution coronary stent implantation within one year

11. Congestive heart failure or uncontrolled Angina pectoris;

12. Platelet reduction (platelet count less than 10000/mm3);

13. Symptomatic non-traumatic intracranial bleeding, any other bleeding disorder, bleeding tendency or clotting dysfunction;

14. History of gastrointestinal ulcers, gastrointestinal bleeding, or surgical history within the last 3 months;

15. Severe complications of non-cardiovascular and life expectancy less than 3 months;

16. Have malignant tumors which in course of treatment;

17. History of allergies to SanqiTongshu;

18. Aspirin users have any of the following conditions: (1) History of allergy to aspirin or salicylic acid analogues (2) Pepsi ulcers (3) asthma or asthma history caused by aspirin;

19. Allergy history of clopidogrel;

20. History of alcohol or drugs abuse in the past 12 months;

21. Pregnant, lactating women, or women who do not take effective contraception;

22. There are other serious diseases or abnormal laboratory results who is not suitable to participate the study;

23. Those who are participating in other clinical trials or clinical trials completed in past 3 months;

24. Patients do not understand the study, or are unable to/unwilling to follow the provisions of the clinical trial.

Related Conditions & MeSH terms

• Antiplatelet Effect
• Cerebral Infarction
• Ischemia
• Ischemic Stroke
• Stroke

Intervention

Drug:
• Sanchitongshu
SanchiTongshu capsule produced by Chengdu Huashen Group Co., Ltd.
• Aspirin
Aspirin produced by Bayer Co., Ltd.
• Clopidogrel
Clopidogrel produced by Shenzhen Salubris Co., Ltd.
• placebo of Sanchitongshu
SanchiTongshu palcebo capsule contained dark brown muscovada sugar and the same inactive excipient (starch). Produced by Chengdu Huashen Group Co., Ltd.

Locations

Country	Name	City	State
China	Zhenguo Liu	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	New stroke attack	Any type of stroke events attack or recurrence	24 hours